Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Latest Senate FDA Reform Bill Would Delay Guidance On Mobile Health Apps

This article was originally published in The Gray Sheet

Executive Summary

The Senate user fee reauthorization and FDA reform bill, formally introduced May 15, includes several new provisions, including a moratorium on FDA issuing final guidance on mobile medical apps. The bill should see action on the Senate floor this week.

You may also be interested in...



Challenges Abound In Creating Regulatory Framework For Mobile Medical Apps, Health IT

FDA plans to release guidance for mobile medical apps ahead of a larger regulatory framework on health information technology, according to an agency official.

FDA Subject To More Oversight Following User Fee Bill Passage

The legislation, awaiting the signature of the president, will bring greater scrutiny of device center activities by Congress and industry.

A Successful Pharma Mobile Strategy Means Matching The Right Info To The Right Device

Pfizer and Sanofi representatives discuss how pharmaceutical firms can best leverage mobile platforms to reach consumers. Elements to consider include ensuring a mobile website makes a good first impression, delivering a message that is simple and on-point, integrating the mobile platform strategy with the brand strategy and considering how best to use tools like text messaging and apps.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

MT031234

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel